Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and ManagementSteven Y. C. Tong, Vance G. Fowler, Joshua S. Davis et al.|Clinical Microbiology Reviews|2015Cited by 5.1k
Large-scale chemical–genetics yields new M. tuberculosis inhibitor classesEachan O. Johnson, Deborah T. Hung, Emily LaVerriere et al.|Nature|2019Cited by 179
Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With SepsisJoel M. Dulhunty, Megan Ratcliffe, Stephen J. Brett et al.|JAMA|2024Cited by 139
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old FoeSteven Y. C. Tong, Adrian Dunlop, Jocelyn Mora et al.|Clinical Infectious Diseases|2022Cited by 98
Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing <i>Enterobacter</i> spp, <i>Citrobacter freundii</i>, <i>Morganella morganii</i>, <i>Providencia</i> spp, or <i>Serratia marcescens</i>: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)Adam G. Stewart, Gabriel Yan, Gail Brenda Cross et al.|Open Forum Infectious Diseases|2021Cited by 91